| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
| FC | 1:50-1:200 |
Urokinase-type plasminogen activator (uPA/PLAU) serves as a critical serine protease in the plasminogen activation system, playing essential roles in extracellular matrix remodeling, cell migration, and tissue invasion. Beyond its established function in fibrinolysis, PLAU has emerged as a significant factor in cardiovascular research and cancer biology, where its expression correlates with tumor progression and metastatic potential, making it a valuable biomarker for investigating disease mechanisms.
This recombinant monoclonal antibody, clone 12D11, offers researchers the reproducibility and consistency that sequence-defined production provides. Unlike traditional hybridoma-derived antibodies, recombinant manufacturing ensures lot-to-lot uniformity, allowing you to maintain experimental continuity across long-term studies without the variability that can compromise data interpretation.
Validated for immunohistochemistry and flow cytometry applications, this antibody demonstrates reliable performance across multiple experimental contexts. IHC validation in paraffin-embedded human prostate cancer and colorectal cancer tissues at 1:50 dilution confirms its utility for studying PLAU expression in clinically relevant tumor samples using standard citrate buffer antigen retrieval protocols. Flow cytometry validation using PC-3 prostate cancer cells shows clear positive signal separation from isotype control, supporting its application in quantitative cell-based analyses of PLAU expression.
The human IgG1 isotype format, combined with affinity chromatography purification, delivers a reagent suitable for detection systems utilizing anti-human Fc-specific secondary antibodies. Supplied in a glycerol-based PBS buffer for optimal stability, this antibody supports researchers investigating PLAU biology in cardiovascular disease, tumor microenvironment dynamics, and metastatic processes where plasminogen activation pathways influence disease outcomes.
Email: support@cusabio.com
Distributors Worldwide